MD Anderson and TESARO form immuno-oncology collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER and TESARO Inc. announced a collaboration to discover and develop small molecule product candidates against immuno-oncology targets, through the cancer center’s Institute for Applied Cancer Science. Under the agreement, TESARO will receive exclusive worldwide rights to develop and commercialize any small molecule product candidates that result from this collaboration. MD Anderson...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

ā€œWe’ve always argued that money comes and goes, but if you lose a generation of scientists—you can’t buy them back,ā€ said Kelvin Lee, director of the Indiana University Simon Comprehensive Cancer Center. 
Joni D. Nelson, assistant director for the Office of Workforce Development at the MUSC Hollings Cancer Center, remembers the exact day a switch went off in her head and her career took a turn towards finding ways to improve public health.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login